Christopher Paul Riley
Known title: Executive Vice PresidentCIK: 0002000111
Associated companies
Transaction History
| DHR | ▲ Buy | Grant | 41,072 | $0 | 8/4/2026 | View on chart |
| DHR | ▲ Buy | Grant | 6,172 | $0 | 3/1/2026 | View on chart |
| DHR | ▼ Sell | Tax Withholding | 1,115 | $235K | 3/1/2026 | View on chart |
| DHR | ▼ Sell | Tax Withholding | 242 | $51K | 2/24/2026 | View on chart |
| DHR | ▲ Buy | Grant | 1,046 | $0 | 2/4/2026 | View on chart |
| DHR | ▼ Sell | Tax Withholding | 640 | $143K | 2/2/2026 | View on chart |
| DHR | ▲ Buy | Option Exercise | 7,801 | $597K | 4/30/2025 | View on chart |
| DHR | ▼ Sell | Open Market | 7,801 | $1.5M | 4/30/2025 | View on chart |
| DHR | ▼ Sell | Open Market | 8,004 | $1.6M | 4/30/2025 | View on chart |
| DHR | ▲ Buy | Grant | 12,034 | $0 | 3/1/2025 | View on chart |
| DHR | ▼ Sell | Tax Withholding | 348 | $73K | 2/24/2025 | View on chart |
| DHR | ▼ Sell | Tax Withholding | 3,074 | $659K | 2/3/2025 | View on chart |
| DHR | ▼ Sell | Tax Withholding | 320 | $84K | 5/15/2024 | View on chart |
| DHR | ▼ Sell | Tax Withholding | 539 | $137K | 2/26/2024 | View on chart |
| DHR | ▲ Buy | Grant | 2,367 | $0 | 2/21/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Danaher Expands AI Integration in Scientific Research
Danaher has announced a partnership to integrate AI into scientific research workflows, a move that could enhance its diagnostic and drug discovery capabilities. With Q3 earnings approaching, investors are watching to see if this strategic shift supports the company's recovery narrative. The stock currently trades near its 52-week high, reflecting optimism about these operational improvements.
Danaher Expands AI Integration in Scientific Research. Danaher has announced a partnership to integrate AI into scientific research workflows, a move that could enhance its diagnostic and drug discovery capabilities. With Q3 earnings approaching, investors are watching to see if this strategic shift supports the company's recovery narrative. The stock currently trades near its 52-week high, reflecting optimism about these operational improvements.